You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The deals with Covance, NeoGenomics Laboratories, and Navigate BioPharma Services aim to expand access to NanoString's PanCancer IO 360 Gene Expression Panel.
Idylla molecular testing instruments will be placed at Covance sites to support customer needs for clinical trials and to validate and implement companion diagnostic applications.
LabCorp's Covance business plans to offer single-cell services on Mission Bio's platform to pharma and to explore its use in companion diagnostics.
Total revenues reached $2.54 billion during the quarter, while LabCorp Diagnostics' revenues rose more than 8 percent to $1.80 billion.
As the development of drugs and diagnostics are increasingly beginning to merge, Covance is aiming to dedicate resources to capture market share.
The company reported $2.27 billion in revenues and updated its year-end guidance.
The company reported $2.22 billion in second quarter revenues, with $620.8 million attributable to the Covance acquisition.
LabCorp subsidiary Covance will process patient samples in Singapore and send them to Epic's San Diego lab for CTC analysis.
Acquisition of the contract research organization, since closing on Feb. 19, contributed $267.2 million to LabCorp's revenues, driving 18.7 percent growth year over year.
According to CEO David King, the deal allows LabCorp greater access to therapeutic areas, as it forecasts $100 million in incremental CDx revenues by 2018.
The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.
Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.
Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.
In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.